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Abstract 
The relevant therapeutic outcomes obtained with the use of proton pump inhibitors for             
the treatment of gastric conditions have an important reflection on the prescribing habits             
of clinicians of primary and secondary care organizations. With the attempt to reduce             
their financial impact on the health systems, generic medications, obtained both from            
tradition distribution chain and from parallel import, have represented the main type of             
proton pump inhibitors used in clinics recently. The effect of parallel import and the use               
of the internet as an international distribution network significantly facilitates the entry            
of falsified medicines in the official channels of distribution. Since the           
interchangeability of different omeprazole preparations has been previously questioned,         
in this study we used Raman and ​1​H-NMR to characterise different omeprazole and             
esomeprazole formulations produced by different manufacturers and obtained from both          
traditional pharmacies and from unlicensed internet market in order to establish if any             
differences could be found to substantiate any different clinical performances. A           
chemometric study of Raman spectra allowed partial separation indicating that there are            
not sufficient chemical differences for PCA groups to be established using this            
analytical approach and for these specific medications. On the contrary, NMR           
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investigations allowed the identification of impurities in internet samples, not detected           
by the Raman analyses, making this technique a valid candidate analytical tool to adopt              




Omeprazole, generic, falsified medicines, unlicensed internet market, Raman, NMR. 
 
1. Introduction 
Proton pump inhibitors (PPIs) are a family of medications that block or diminish the              
production of gastric acid acting on the proton pump present in gastric parietal cells [1].               
Omeprazole (Fig.1) and esomeprazole belong to such a family, being omeprazole a            
racemic mixture and esomeprazole the related Levo-enantiomer [2]. In the intracellular           
canaliculi of the parietal cell, particularly acidic, omeprazole is concentrated and           
converted to the active form, being a weak base, and interacts with H​+​-K​+​-ATPase, the              
proton pump, reversibly reducing or blocking its activity [3]. This influences the final             
step of the gastric acid secretion process and acts irrespectively both in the basal acid               
secretion and in the one instigated by stimuli. PPIs are quickly active and with a unique                




Fig. 1 (a) Omeprazole and (b) esomeprazole, chemical structure, with the S being             




Because the reflux of the acidic gastric content into the oesophagus plays a major role in                
the pathogenesis of symptoms of GERD (gastro-oesophagal reflux disease) and lesions           
of erosive oesophagitis, acid suppression with a PPI is currently a mainstay of             
anti-reflux therapy [3, 4]. There is a strong correlation between the degree of acid              
suppression provided by a given drug and its efficacy. The superiority of PPIs over              
other drugs (antacids, prokinetics and H2-receptor antagonists) has now been          
established beyond doubt, both for short- and long-term treatment [5]. Nevertheless,           
patients with erosive esophagitis are more reactive to PPIs than those with non-erosive             
reflux. Sometimes the action of PPIs in patients with atypical gastric condition is             
reduced to a reduction of the symptomatology of heartburn. Different studies conducted            
on the safety of use of PPIs both in short and long periods have provided reassuring                
conclusions on their safety [6-9]. PPIs have shown improved healing yield in case of              
severe erosive esophagitis, with quicker relief of the associated symptomatology [9].           
The successful results obtained with the use of PPIs for the treatment of erosive              
esophagitis is having an important reflection on the prescribing habits of clinicians of             
primary and secondary care organizations in the United Kingdom [10]. The vast            
therapeutic success of PPIs has incredibly increased their use both in primary and in              
secondary care. With the attempt to reduce their financial impact on the health system,              
generic medications, obtained both from tradition distribution chain and from online           
import, have represented the main type of PPIs used in clinics recently [11, 12].  
The effect of parallel import and the use of the internet as an international distribution               
network significantly facilitates the entry of forged medications in the official channels            
of distribution [13]. The Food and Drug Administration (FDA) released a study related             
to the effect of the internet market on the diffusion of counterfeit medications. [14, 15].               
Based on a report from WHO [16, 17], half of the medications traded on the internet                
sites are fakes. Because of the anonymous nature of the online market, the risks that               
criminals run operating in this sector is considerably high, being the investigations            
performed by the law enforcement authorities significantly more difficult and          
consequently less effective [18]. 
The Falsified Medicines Directive (FMD), delegated regulation 2011/62/EU [13], is a           
European Union legislation which aims to protect patients by preventing falsified           
medicines from entering the supply chain improving the security of the production and             
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delivery of medications across Europe. Regulatory authorities continue to locate          
falsified medicines in the official supply chain, although unlicensed internet sites have            
now become the main route for trading falsified medicines to the public. Under the              
FMD, all new containers of medicines commercialised in Europe from February 2019,            
will present two safety features: an anti-tamper device (ATD) and a unique identifier             
(UI) code, in the form of a 2D data matrix barcode. Nearly all prescription-only              
medicines (POM) with a marketing authorisation are in the scope of FMD, with only a               
few exclusions. All non-prescription medicines are out-of-scope, with the exception of           
two omeprazole products, which were subject to falsification in the past [13] 
 
Gastroenterology is one of the clinical areas where there are concerns among            
health-care professionals and patients that not all generic medications can be equally            
clinically effective [1]. Several clinical trials have been performed comparing different           
generics, in order to evaluate any therapeutic differences. In [8, 9] Shimatania et al              
compared, in prospective, randomized, open-label, crossover studies, the        
acid-suppressive effect of generic omeprazole [8] and lansoprazole [9] with that of the             
original brand. In both studies, the intragastric pH was measured at the regular interval              
of time. Values of stomach acidity showed figures above pH4 for 24h cycles. These              
were significantly higher with the administration of any PPI formulations compared           
with a placebo, indicating significant differences in acid-suppression effects amongst          
the respective groups of PPIs. This led to the conclusion that acid-suppressive effects of              
some brands of generic omeprazole and lansoprazole are not the same as the original              
ones. 
Besides these clinical studies, no information has been found in the literature            
concerning the chemical characterization of different PPIs, obtained both from          
authorised pharmacies and from non-authorised websites, aimed to investigate if          
different clinical features are associated with specific chemical characteristics. In fact,           
generic drugs are actually chemically equivalent to their brand-name counterparts or           
among them just in terms of active ingredients, but they may differ in peripheral              
features, such as inert binders and fillers, shape, colour and the specific manufacturing             
process, which could lead to diverse clinical responses [19-21]. This scenario highlights            
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the need for the development of an analytical approach capable of discriminating            
amongst the different proton pump inhibitors.  
Since the interchangeability of omeprazole and esomeprazole preparations produced by          
different manufacturers has been previously questioned, in this study, Raman and           
1​H-NMR spectroscopies have been used to characterize different omeprazole and          
esomeprazole formulation produced by different manufacturers and obtained from both          
traditional pharmacies and from the internet market in order to establish if any             
differences could be found to substantiate any different clinical performances.  
 
2. Materials and Methods 
 
2.1. Materials 
Omeprazole, (5-methyl-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]   
sulfonyl}-1H-benzimidazole) and esomeprazole   
(6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimida
zole) from seven 20mg anonymised oral formulations (defined as A to G) have been              
used: five of these were omeprazole (A, B obtained from traditional pharmacies, and C,              
D, E obtained from unlicensed internet websites) and two were esomeprazole ( F, G              
obtained from traditional pharmacies).  
Sixteen tablets of each PPIs were analysed internally and externally by Raman and             




2.2.1. Raman analysis 
Raman analysis was performed on a FORAM 685-2 instrument with a laser operating at              
532 nm. The Raman instrument was also equipped with an integral video microscope             
with magnification 50x. Analyses were performed between the wavenumbers 2000 and           
800 cm​-1​. SERS-Raman enhances the sensitivity of standard Raman scattering by           
depositing a metal colloid on the surface of the sample being analysed. For this part of                
the investigation, silver colloids were prepared as follows: silver nitrate was reduced            
using sodium citrate in water, and concentrated by centrifuging at 5000 rpm. The eight              
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tablets for SERS analysis were covered with 2 µL of the prepared colloid solution and 2                
µL of NaCl 1M as an aggregating agent. To test the external side, the tablets were                
coated with the silver colloid preparation and aggregating agent and exposed to the             
laser. This was again repeated five times for each tablet, with the laser directed at a                
variety of external sites, to achieve the 40 representative analyses for each PPIs. To test               
the internal side, the tablets were broken in half prior to the addition of the silver colloid                 
and aggregating agent and again exposed to the laser five times for each tablet.  
In order to find the optimal setting for the Raman analysis, samples were submitted to               
the laser exposure for different acquisition times. Spectra of the same samples were             
recorded at different interval of exposure time, ranging from 1 second to 5 minutes.              
Optimised spectra could be obtained from 60 seconds onwards of acquisition time,            
which was, consequently, chosen as the acquisition time for all the following analyses. 
 
2.2.3. Nuclear Magnetic Resonance 
1​H NMR spectra were obtained from a Bruker Avance 500 at 500.1 MHz using TMS as                
the internal standard and MeOD as solvent. Chemical shifts for proton resonances were             
given in ppm (δ). Signal multiplicity was characterized by s (singlet), d (doublet) and dd               
(double doublet). NMR spectra were recorded using 128k complex points and a            
recovery time of 4 seconds 16 transients were generally sufficient to achieve good             
signal-to-noise. In a typical sample preparation, pills were mechanically ground to           
obtain a fine powder. The powder was suspended in MeOD (1 mL) and then filtered               
through a syringe filter (45 µm) to obtain a solution containing the active principle.              
Reference samples of each of the most common excipients (lactose, cellulose, starch)            
were prepared in MeOD and used to identify characteristic signals in samples 
 
3. Results 
3.1. Raman spectroscopy of omeprazole and esomeprazole formulations  
A typical SERS spectrum related to the analysis of the surfaces of the omeprazole and               
esomeprazole tablets investigated is shown in Fig. 2. Tablets from all the seven different              






Fig. 2. Typical SERS analysis of omeprazole for sample A, external tablet surface             
with some of the typical bands found.  
 
At 890 cm​-1 a small but sufficiently defined peak, possibly related to the stretching of               
the ether groups present in the two aromatic rings of the omeprazole molecule could be               
observed. In the region around 950 cm​-1 smooth peaks, possibly assigned to the             
stretching of the C-C, could be also observed. In the region around 1100 cm​-1 a signal                
assigned to the stretching of the ether groups can also be observed. In the region around                
1260 cm​-1 a peak which may be referred to the stretching of the thiocarbonyl group can                
be observed. In the region of 1300 cm​-1 a peak, possibly assigned to the symmetric               
stretching of the chain vibrations of the two aromatic rings, can be identified. At 1380               
cm​-1 a strong peak possibly due to the symmetric bending of methyl groups can also be                
identified. The asymmetric bending of the same groups laid in the region between 1440              
and 1500 cm​-1 can explain the signals recorded in the region 1460-1475 cm​-1​. At 1500               
cm​-1 a peak probably to be referred to the asymmetric bending of the methyl group. At                
1632 cm​-1 ​ peak possibly related to the stretching of the aromatic rings [22, 23]. 
 
To perform the analyses of the internal part of the tablets, the seven different              
formulations were manually broken in half and then submitted to the preparation for             
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SERS analysis as indicated previously. All formulations present signals (Fig. 3) which            




Fig. 3. Typical SERS analysis of omeprazole, sample B, internal tablet content with             
some of the typical bands found.  
 
The differences found between surface and inner analyses can be attributed to a lower              
concentration of the drug on the surface mixed with coating agents. 
The conventional Raman spectra of both the tablet surfaces and inner tablet body were              
also performed. These spectra show common features with those SERS previously           
analysed but lower intensity for main peaks (shown in figure S1 in supplementary             
material).  
To aid in the interpretation of the vast amount of Raman shifts generated, for both               
SERS and conventional Raman, a Principal Component Analysis (PCA) was used (Fig.            
4). The PCA scatterplots of the SERS data obtained by analysis of the external side of                
the omeprazole and esomeprazole tablets shows partial identifiable distribution profiles          
for some of the classes of samples investigated. Principal component (PC) 1 accounted             
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for 93.22% of the variation, with PC2 and PC3 being responsible for 5.31% and 0.65%               
respectively. PC1 and PC2 were therefore responsible for an accumulative 98.53% of            
the variation. The PPI formulations were separated due to their individual association            
with the two main components. Tablets B, F and G can be seen to partially separate                
over the value of PC2. G is dispersed sparsely at lower PC2 value; F is located at a                  
central PC2 value whilst B clusters at a higher value of PC2. The cloud of data                





Fig. 4. Two-dimensional score plot from the Principal Component Analysis of the            
SERS samples for omeprazole and esomeprazole on external tablet. Omeprazole          
(A, B obtained from traditional pharmacies); C, D, E obtained from unlicensed            
internet websites); F, G (obtained from traditional pharmacies). 
 
Predictive accuracy of the PCA model obtained was validated via cross-validation and            
leave-one-out approach. The total error rate of the predictive model evaluated via            
cross-validation accounted for 78%. Furthermore, the predictive accuracy of the model           
was also tested via leave-one-out validation with a cumulative error rate of 80%.  
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PCA of the SERS data obtained by analysis of the internal side of the PPI tablets shows                 
no clear distribution profiles for the classes of samples studied (see figure S2 in              
supplementary material). Principal component (PC) 1 accounted for 95.83% of          
variation, with PC2 and PC3 being responsible for 3.76% and 0.45% respectively. PC1             
and PC2 were therefore responsible for an accumulative 99.59% of the variation. The             
total error rate of the predictive model evaluated via cross-validation accounted for            
70%. Leave-one-out validation on this set of data reported a cumulative error rate             




3.2. ​1​H-NMR of omeprazole formulations  
In light of the similarity on some of the Raman spectra obtained and to further gather                
additional information on the chemical structures of the samples, the use of proton             
NMR was considered to elucidate more chemical diversities. 
In its molecular structure, omeprazole presents two sources of structural differentiation           
when performing proton NMR. Firstly, omeprazole is a chiral molecule since it has a              
diastereogenic centre located on the thiocarbonyl sulfur atom. The second source of            
diversity is that it presents tautomerisms [24] 
Proton nuclear magnetic resonance of a pure omeprazole standard is reported in Fig. 5.              
While Raman spectroscopy gives information on the functional groups present in the            
compound, NMR spectroscopy can determine structural features of the compounds. The           






Fig. 5. ​1​H NMR of omeprazole pure standard used to represent in details the peaks               
assignment (500 MHz, MeOD, 298K).  
 
Proton nuclear magnetic resonance of the three internet omeprazoles analysed was           
compared to a European pharmaceutical reference sample is reported in Fig. 6. The             
NMR spectra for the samples analyzed was similar but with a few elements of              
differentiation. Characteristic peaks at 8.2, 7.5, 7.1 and 7.0 ppm were observed            
corresponding to omeprazole protons 7, 2, 4 and 3 respectively, as reported by             
Claramunt et al in an assessment study conducted using omeprazole standard [24].            
These peaks are present in all the different classes of samples analyzed. Samples C and               
D showed two singlets at 7.6 and 7.7 ppm, respectively, close to the omeprazole doublet               
at 7.5 ppm assigned to proton 2. These two singlets are indicative of additional aromatic               
molecules present as impurities. The region between 6.5 and 4.75 ppm is where the              
strongly de-shielded methyl/methylene protons directly attached on the pyridinylic         
moieties could be found. The signals located in the area around 5 ppm are related to the                 
hydroxyl groups present in the excipients (as identified from comparison against           
reference samples shown in supplementary materials Figure S3), mainly lactose,          
cellulose and starch for all the formulations studied.  
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The ​1​H NMR analyses of the generic classes of omeprazole investigated present some             
remarkable differentiation (Fig. 6). Samples E and B showed the same formulation, with             





Fig. 6. ​1​H NMR of the omeprazoles (500 MHz, MeOD, 298K). From top to bottom               
samples: A, B, E, F, C and D. At 7.6 and 7.7 ppm, samples C and D present two                   
singlets associated with aromatic compounds different than omeprazole structure. 
 
In general, all samples analyzed resulted to be very similar with similar amounts of both               
lactose and cellulose. However, unexpectedly, samples C and D contain extra signals in             
the aromatic region that most likely correspond to some impurity given that common             
excipients used on omeprazole formulations have no aromatic protons.  
 
3.3.1. Study of the internet samples C and D. 
The ​1​H NMR spectra obtained from samples C and D showed two signals at 7.6 and 7.7                 
ppm not found in the other samples that can be related to additional aromatic substances               
not present in the other formulations. It could be speculated that these aromatic signals              
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correspond to impurities produced during the synthetic process of the omeprazole active            
pharmaceutical ingredient. Another possible cause for the presence of these impurities           
is that they originated as contamination from the specific manufacturing process for            
samples C and D. There are several omeprazole known impurities that are produced             
during the synthetic process and therefore methodology to identify its presence in            
omeprazole samples has been developed [25]. A comparison of the structure of known             
omeprazole impurities with the ​1​H NMR of samples C and D hinted at 4-Desmethoxy              
omeprazole (also known as omeprazole impurity B) as being the compound responsible            
for the extra two singlets in the aromatic region of samples C and D. Indeed a                
reverse-phase LC-MS analysis of samples C and D (Figures S4 and S5 in             
supplementary material) identified the presence of a compound with m/z = 316 Da that              
matches with the mass of 4-Desmethoxy omeprazole (see SI). Again the LC-MS traces             
were identical for samples C and D, indicating that both samples have an extremely              
similar formulation. 
Notwithstanding the possible causes that have produced the two aromatic impurities,           
their presence in the composition of the final pharmaceutical products, ready to be used              
by patients, raises suspects on the quality of the medications themselves. These two sets              
of samples have been both purchased off internet market from un-official websites, not             
regulated by any government authorization for the dispensing of medications. Samples           
C and D were purchased from the Asian region, through a European available website.              
In this geographic area, between 1999 and 2004, the ratio of fraudulent medications             
boosted drastically, with an increased of forged medications sales range from 10% to             
more than 30% of the national legal market. Because of the anonymous nature of the               
online market, the risks of entry into the market of medications of uncertain quality is               
remarkably high, being the quality control performed by the government authorities           
significantly more difficult and consequently less effective. 
The manufacturing production of medicines is extremely articulated but it can be            
divided into two principal stages: the primary manufacturing stage, where the active            
pharmaceutical ingredient is manufactured, and the secondary manufacturing stage,         
where the active pharmaceutical ingredient (API) is mixed with other ingredients to            
prepare the final pharmaceutic formulation. Impurities in samples D and C could have             
derived from one or both of these stages. 
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During the very last World Health Assembly, it was agreed to embrace the definition of               
‘Substandard and Falsified medical products’ as an official term to be used by the              
member states with a most recent change in terminology introducing the classification            
of ‘substandard’ and ‘falsified’. The first defines those official medical products that            
lack reaching the required standards of quality and/or to meet the necessary            
specifications. Falsified identifies those medical products that intentionally give false          
information on their nature, origin and structure. It is not clear at this stage of research if                 
D and C could be classified as substandard or, worse, as falsified, but it seems probable                
that the lack of quality control that has allowed to input into the market these               
medicinals, containing aromatic products, and as such usually biochemically active,          




The analysis of the seven different PPIs does not give significantly distinctive spectra             
when studied via conventional Raman spectroscopy, both internally and externally.          
Using SERS, however, it was possible to observe an improvement in the            
characterisation of the spectra, especially on the analyses of the surfaces of the             
specimens. Although an omeprazole standard was not used in this study, previously            
published spectra compared to those obtained in this investigation showed that there are             
differences that can be accredited to the excipients added to the formulations [26-28].             
All the spectroscopic analyses obtained from the internal and external parts of the             
samples were quite alike although some differences in quality and resolution could be             
noticed, due to a possible coating effect on the tablets. Previous spectroscopic studies             
reported that the concentration of active ingredients in solid formulations resulted to be             
non-homogeneously spread across from external to internal areas [29, 30]. SERS           
analyses of the internal side seem to show the same peaks but more pronounced than the                
external area. This could be related to the manufacturing processing, effectively giving a             
higher concentration at the internal area compared to that of the surfaces.  
The spectra obtained from all the spectroscopic investigations did not produce a neat             
visual differentiation amongst the seven classes of samples investigated. It could be            
speculative to suggest that solid formulations often contain very low doses of API in              
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comparison with the dosage of excipients used, which can present analytical challenges            
in terms of differentiation [30]. From the patient information leaflets, the list of             
excipients were similar with the only difference of hypromellose for the preparations F             
and G. Active pharmaceutical ingredients (APIs) can exist in different polymorph states,            
each one with specific chemical and physical properties which can affect directly their             
clinical pharmacological features. Manufacturer processing, handling, and storage can         
affect the polymorphic form state of the solid medication. Transformations can           
additionally occur due to interactions of APIs with excipients. Pharmaceutical solid           
forms can incorporate surface coating agents, with the function to act on the drug              
release performances or to improve the swallowability, and signals arising from such            
coating agents can cover API’s ones. The thickness of the coating has a direct effect on                
the swamping of the API’s signal too [31]. Numerous APIs include aromatic functional             
groups in their structure, which produce symmetric vibrational modes making the           
molecule strong Raman scatterers. On the contrary, many excipients are aliphatic, with            
modest Raman activity, which can masks the APIs Raman response [32]. The weights             
of the tablets for all the different formulations were ranging between 399 and 410 mg,               
leading to a ratio API/excipients of only 0.05. The limited differentiation in the results              
obtained from the spectroscopic analyses was taken into consideration as a possible            
result obtained, because of the similar nature of the samples investigated. This was the              
justification to use chemometric analysis.  
Cellulose, lactose and starch are the main excipients used in all of the formulations              
studied and all present a high ratio of hydroxyl groups, which could be masking with               
their broad peaks components of the omeprazole molecules. This is substantiated by the             
asymmetric stretching C-O-C and C-OH peaks found in the region around 1100 cm​-1             
from the sugar rings of the excipients [33, 34]. Notwithstanding the great resemblances             
amongst the spectra of the seven different classes of analytes, the statistical analysis of              
these spectroscopic data allowed the minor differences to be significative, even though            
only very few differences could be effectively being exploited. There were limited            
regions of the spectra obtained that could be associated with the individual omeprazole             
core structure. This could be because both the core of the molecules for all the classes of                 
omeprazole is the same and that the excipients employed in the manufacturing of the              
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solid formulations, covering any of the more noticeable differences, are indeed the same             
or belonging to sugar classes with same functional groups. 
The scoreplots generated with the different Principal Components gave a visual           
clustering of the different PPIs, but, indeed, only little separations could be observed.             
Throughout PCA analysis of all spectroscopic investigations, the PPIs did not separate            
and clustered tightly, but they were rather spread in the same areas, overlapping. Only              
in the PCA obtained from the SERS analysis of the external areas, B, F and G showed                 
to be clustered in separated groups. This evidence is in line with previous articles that               
reported how the enhanced sensitivity of SERS over conventional Raman leads to an             
improved selectivity which would allow for better discriminatory abilities [35, 36]. The            
PCA variability ranged around 98-99% for all the categories of set of experiments             
performed. 
In this case, cross-validation and leave-one-out used to validate the accuracy of the             
predictive models gave non-positive outcomes, with a considerable amount of error.           
The total error rates for all the PCAs executed were well over 75%, both from               
cross-validation and from leave-one-out evaluation, showing that the multivariate         
analysis in this study did not present good discrimination power. There was no strong              
spectroscopic evidence in the factor loadings for the omeprazole formulations (not           
included). This is not unexpected given spectral interferences from the excess bulk            
agents present in the formulation already mentioned. These results substantiate the fact            
that the different PPI formulations studied are extremely similar. 
Because of the need for additional information on the chemical structures of these             
samples to be able to discriminate differences amongst them, the use of NMR was              
considered to elucidate more chemical diversities. While Raman spectroscopy directly          
targets each part of the molecular structure of a given compound providing information             
related to the functional groups present, NMR gives information on the chemical            
structure of the analyte. NMR analyses of the seven different PPI preparations            
investigated presented some remarkable point of discrimination. E and B showed same            
formulation, with slightly different ratios. C, D, E, and B resulted to be very similar,               
with a similar amount of both lactose and cellulose. On the contrary, sample A seemed               
to be the only one not containing cellulose. F and G, both Levo-isomers of omeprazole               
racemate, contained the same chemicals, however, G contained considerably less API in            
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the formulation. Both presented the presence of lactose and cellulose. G and F contain              
another aliphatic compound, probabily methacrylate, not found in the other classes of            
samples. Samples C and D resulted to be identical in each other, however, when              
compared to the rest of the samples contain an extra aromatic compound. The two              
singlets identified in the aromatic region of their ​1​H NMR spectra were assigned to              
4-Desmethoxy omeprazole using LC-MS and were otherwise not found in the other            
formulations. Samples C and D were purchased from uncertified online websites, and            
the parcels received were both coming from Asian regions. Because of the nature of the               
impurities tracked in these two generic medications, it is plausible to consider them as              





5. Conclusions  
In this study, it was shown that Raman with the aid of chemometric methods did not                
offer enough analytical resolution to differentiate the different PPIs studied.  
Further investigation by proton NMR of the backbone of the molecular structure of the              
PPI formulations highlighted the similarity of the samples, with C and D being in effect               
the same product, probably manufactured by the same plant and then commercialised            
under two different marketing names. E and B resulted nearly identical, showing a very              
similar NMR diagram, as well. 
NMR investigation allowed to notice in the internet samples C and D the presence of               
aromatic impurities, not detected during the Raman analysis. The problem of the            
uncertain quality of medications purchased online has been previously emphasised in           
this study, showing how probable it could be to obtain low quality medications when              
bought from un-authorised online sources. 
These results are particularly relevant highlighting the fact that spectroscopic          
techniques, such as Raman, typically used in standard quality control tests in the             
pharmaceutical industry may miss impurities in medications produced in different          
manufacturer plants under different quality regimes. This opens the possibility to adopt            
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NMR in the list of analytical technique that can help to assure the quality of medicines,                
tackling the problem of falsified and substandard medications.  
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